# Atenolol

Drug · id `cardio:atenolol` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Tenormin

Browse, organ or system: Heart  
Browse, condition area: High blood pressure; Coronary and vascular disease  

## In plain language

Atenolol is a beta-blocker taken by mouth. The US label read, for Tenormin, lists three uses: hypertension, to lower blood pressure; the long-term management of patients with angina pectoris; and, in hemodynamically stable patients with definite or suspected acute myocardial infarction, reducing cardiovascular mortality.

## Technical summary

RxNorm ingredient 1202; UNII 50VV3VW0TI. MeSH descriptor D001262 is Atenolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Upsher-Smith Laboratories, LLC label for TENORMIN (atenolol), application NDA018240, effective 2025-09-18 in openFDA. Other atenolol labels in openFDA, from generic sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of atenolol (Tenormin) lists an indication: hypertension, angina pectoris, definite or suspected acute myocardial infarction

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of TENORMIN (atenolol), in the Upsher-Smith Laboratories, LLC version dated 2025-09-18 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the long-term management of patients with angina pectoris; and for hemodynamically stable patients with definite or suspected acute myocardial infarction, to reduce cardiovascular mortality.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-08
- Sources:
  1. Supports: openFDA drug label record for TENORMIN (atenolol), Upsher-Smith Laboratories, LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 6e850b1e-28a4-4ff8-8ed7-bb0b29faa28a (manufacturer Upsher-Smith Laboratories, LLC, application NDA018240), returned on 2026-11-08. The label text is dated 2025-09-18 (effective\_time). Other openFDA records of atenolol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226e850b1e-28a4-4ff8-8ed7-bb0b29faa28a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-08T20:37:09Z. Source state: Current. Version fingerprint: 16fc3b394ebc3edfdc3713d69728e637bce0d7771e3e123eb168492146835def.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for TENORMIN (atenolol), Upsher-Smith Laboratories, LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 6e850b1e-28a4-4ff8-8ed7-bb0b29faa28a (manufacturer Upsher-Smith Laboratories, LLC, application NDA018240), returned on 2026-11-08. The label text is dated 2025-09-18 (effective\_time). Other openFDA records of atenolol labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%226e850b1e-28a4-4ff8-8ed7-bb0b29faa28a%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-08T20:37:09Z. Source state: Current. Version fingerprint: 16fc3b394ebc3edfdc3713d69728e637bce0d7771e3e123eb168492146835def.
     How it applies: Effective date of the label text read, 20250918.

## Connected pages

- Atenolol is a beta-adrenergic blocker (FDA established pharmacologic class in RxClass): Beta-blockers (drug class) (`cardio:beta-blockers`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-atenolol-label-indications` and its context]
- FDA label lists reducing cardiovascular mortality in stable patients with definite or suspected acute myocardial infarction as an indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-atenolol-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 3 registry products
- 5 registry trials

## Provenance

Content hash: cc4c887dd5c1e57df4e6422f937acbb52a3bf8d2b1ef70454003e4cfd158085e
Last substantive edit: 2026-11-08
Evidence last checked: 2026-11-08
